Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.
Jakubowiak AJ et al. Hematology. 2017 May 25:1-7. doi: 10.1080/10245332.2017.1328165. [Epub ahead of print].

Clinical conditions responsible for hyperviscosity and skin ulcers complications.
Caimi G et al. Clin Hemorheol Microcirc. 2017 May 19. doi: 10.3233/CH-160218. [Epub ahead of print].

Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.
Maharaj S et al. Expert Rev Anticancer Ther. 2017 May 23:1-7. doi: 10.1080/14737140.2017.1330153. [Epub ahead of print].

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: a pooled analysis.
Moreau P et al. Eur J Haematol. 2017 May 15. doi: 10.1111/ejh.12903. [Epub ahead of print].

Metastatic spinal cord compression as the first sign of malignancy.
Wänman J et al. Acta Orthop. 2017 May 11:1-6. doi: 10.1080/17453674.2017.1319179. [Epub ahead of print].

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Kumar S et al. Br J Haematol. 2017 May 9. doi: 10.1111/bjh.14733. [Epub ahead of print].

Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.
Chaudhry HM et al. Mayo Clin Proc. 2017 May;92(5):838-850. doi: 10.1016/j.mayocp.2017.02.003.

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Laubach JP et al. Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14708. [Epub ahead of print].

Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Vidisheva AP et al. Support Care Cancer. 2017 Apr 28. doi: 10.1007/s00520-017-3732-6. [Epub ahead of print].

Combined proximal tubulopathy, crystal-storing histiocytosis, and cast nephropathy in a patient with light chain multiple myeloma.
Wu CK et al. BMC Nephrol. 2017 May 25;18(1):170. doi: 10.1186/s12882-017-0584-8.